- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04441229
Mobile Attentional Bias Modification Training in Pediatric MS
A Prospective, Observational Study of Mobile Attentional Bias Modification Training (ABMT) in the Pediatric Multiple Sclerosis (MS) Population
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 12-24 years
- Confirmed Diagnosis of Multiple Sclerosis with onset < 17 years and 11 months (defined by the 2013 International Pediatric MS Study Group (IPMSSG) criteria (Krupp, Tardieu, Amato, Banwell, Chitnis, Dale, Ghezzi, Hintzen, Kornberg, Pohl, Rostasy, Tenembaum, Wassmer, & Sclerosis, 2013) and the 2010 McDonald criteria (Polman et al., 2011).)
- Followed at NYU Multiple Sclerosis Comprehensive Care Center
- Access to a mobile device with iOS (devices will be provided to subjects if this criteria is not met, see section 4.4)
- Active or concurrently enrolled in the ongoing US Network of Pediatric MS Centers Study Consortium
Exclusion Criteria:
- Previous report of an IQ < 70
- Wide-Range Achievement Test-Fourth Edition (Wilkerson, 2006) Reading Subtest standard score <85
- Non-English speaking, learned English in the past three years, or learned English after the age of 12 years
- Not willing to comply with all study procedures
- Insufficient visual and motor ability to operate the intervention and assessments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Group
Patients age 12-24 diagnosed with pediatric-onset Multiple Sclerosis
|
After consent/assent, participants will complete 1 hour-long, in-person or remote, baseline study visit at the Multiple Sclerosis Comprehensive Care Center. During this visit, participants will complete baseline study surveys and a brief computerized attention bias assessment and be trained on the use of the ABMT mobile application. Participants will then complete at-home game play 4 days a week, for 30 days, using an iOS mobile device, approximately 10-15 minutes each day. Subjects will complete weekly online study surveys via REDCap or MyCap (Mobile REDCap Application). At the conclusion of participation, participants will complete online end of study surveys via REDCap or MyCap. Parents of participants will complete surveys at the baseline visit, followed by online surveys at Week 2 and at the end of study. For participants who are 18 years old or older, parental participation will not be required. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of "compliant" participants
Time Frame: 30 days
|
Individuals will be categorized as "compliant" if they interact with the mobile ABMT a minimum of 3 times per week for a minimum of three of the four weeks across the study period of 30 days.
We will consider reaching 50% of compliant participants to indicate that the intervention is feasible for continued study.
Descriptive analyses will be completed to identify any trends in predicting those participants who are most likely to be compliant (ie.
age, gender, baseline function).
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preliminary efficacy composite score
Time Frame: 3 months
|
Investigators convert performance at baseline and study end across study measures SCARED P/C,CDI-II, MASC-2, BDI-II, BAI, and PANAS to scaled age normative scores.
Differences in scaled scores, indicating change following intervention, will be calculated for each compliant participant (defined as above) and averaged for group metrics.
Descriptive analyses will be completed to identify any trends in predicting those participants who are most likely to have improvement in anxiety and mood at study end (ie., age, gender, baseline function) as well as corresponding degree of use of the mobile ABMT with magnitude of benefit.
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Leigh Charvet, NYU Langone Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-00810
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Multiple Sclerosis
-
The Hospital for Sick ChildrenUniversity of Colorado, Denver; Mayo Clinic; Baylor College of Medicine; Children... and other collaboratorsCompleted
-
The Hospital for Sick ChildrenUniversity of Alabama at Birmingham; Queen's UniversityCompletedPediatric Multiple SclerosisCanada
-
The Hospital for Sick ChildrenUniversity of Alabama at Birmingham; Queen's UniversityCompletedPediatric Multiple SclerosisCanada
-
Immune Response BioPharma, Inc.Not yet recruitingMultiple SclerosisUnited States
-
Pontificia Universidade Católica do Rio Grande...Teva Pharmaceuticals USAActive, not recruitingMultiple SclerosisBrazil
-
Istanbul University - Cerrahpasa (IUC)CompletedPediatric Multiple SclerosisTurkey
-
University of California, San FranciscoMassachusetts General Hospital; Mayo Clinic; Baylor College of Medicine; Children... and other collaboratorsCompletedPediatric Multiple SclerosisUnited States
-
Istanbul University - Cerrahpasa (IUC)RecruitingPediatric-onset Multiple SclerosisTurkey
-
The Hospital for Sick ChildrenChildren's Hospital of Philadelphia; University of Alabama at Birmingham; Queen... and other collaboratorsRecruitingPediatric Multiple SclerosisUnited States, Canada
-
The University of Texas Health Science Center,...Microsoft HoustonTerminatedPediatric Onset Multiple Sclerosis (POMS)United States
Clinical Trials on ABMT mobile application
-
Mississippi State UniversityRecruiting
-
Mississippi State UniversityAssociation for contextual behavioral scienceNot yet recruitingHealth-Related BehaviorUnited States
-
George Washington UniversityMedia RezRecruiting
-
University of ReginaCompletedStress | Dementia | Caregiver BurdenCanada
-
University Hospitals Cleveland Medical CenterCompleted
-
Ankara Yildirim Beyazıt UniversityNot yet recruiting
-
University of CadizRecruiting
-
Boston Medical CenterBoston Medical Center Food KitchenWithdrawnDiabetes Mellitus, Type 2 | Pre DiabetesUnited States
-
Instituto de investigación e innovación biomédica...Completed
-
Oslo University HospitalDiakonhjemmet Hospital; South-Eastern Norway Regional Health AuthorityCompletedRheumatic Diseases | Chronic DiseaseNorway